No Data
No Data
Trending Industry Today: CARSGEN-B Leads Gains In Pharmaceutical Companies Stocks
Ascentage Pharma Group International's (HKG:6855) Largest Shareholders Are Retail Investors Who Were Rewarded as Market Cap Surged HK$874m Last Week
Ascentage Pharma Announces Change in Company Secretary
ASCENTAGE-B: Delivery of the exercise of the over-allotment option related to the sale of American Depositary Shares.
ASCENTAGE-B (06855) announced that the underwriter has exercised the over-allotment option and the related delivery of the over-allotment option took place on February 13, 2025 (Eastern Time, USA). The company issued 935,144 American Depositary Shares (representing 3.7406 million related shares according to the representation ratio) at an offering price of $17.25 per share, following the delivery of the over-allotment option, accounting for approximately 1.07% of the total issued common shares. The total proceeds from the optional American Depositary Shares under the offering amount to approximately $16.13 million.
ASCENTAGE-B: Partially exercise the over-allotment option related to the sale of American depositary shares.
ASCENTAGE-B (06855) announced that the underwriter for the initial public offering in the USA has partially exercised its overallotment option, purchasing 935,144 additional American Depositary Shares at a price of $17.25 per share, which is the initial public offering price minus underwriting discounts and commissions. Each American Depositary Share represents four shares of the company's common stock. After the partial exercise of the overallotment option, the total number of American Depositary Shares sold in the offering will increase to 8,260,144, with the total proceeds to the company amounting to approximately $0.1425 billion (before deducting the underwriting discounts and commissions payable by the company).
The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?
Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.
